Cancer Research UK is increasing its annual investment in the Manchester Biomarker Centre from £11m to £17m to accelerate the development of personalized cancer treatments. The facility, located within the University of Manchester’s Paterson building, will use the funding to integrate artificial intelligence, data science, and immunology into its clinical research, while recruiting 100 additional specialized staff members.
How does the proximity to The Christie hospital impact patient care?
The institute’s location at the University of Manchester’s Paterson building provides a direct physical link to The Christie, one of Europe’s leading cancer treatment centers. According to Prof Fiona Blackhall of The Christie NHS Foundation Trust, this proximity allows researchers to move patient samples and cells to the laboratory in minutes. This integration enables a continuous research cycle, moving from basic science to patient trials on a single site. By embedding research within a clinical environment, the center ensures that patient care remains the focal point throughout the discovery process.
The Biomarker Centre focuses on identifying specific genes, proteins, and molecules within a patient’s cancer. These biological markers act as a “fingerprint” for the disease, allowing clinicians to tailor treatment plans to an individual’s unique genetic profile rather than using a one-size-fits-all approach.
Why is the investment in data science and AI considered necessary?
The £6m funding boost is intended to build a platform for long-term discovery, specifically by enhancing expertise in data science and artificial intelligence. Prof Samra Turajlić, director of the institute, stated that this investment will help the center attract top-tier researchers to Manchester. By leveraging AI, the team aims to study cancer at a level of detail previously unattainable, potentially shortening the time it takes to turn laboratory findings into clinical practice. Prof Ashley Blom, vice president of biology, medicine and health at the University of Manchester, noted that this infrastructure is essential for turning “bold ideas into breakthroughs.”
What do these developments mean for future patient outcomes?
The expansion includes funding for two new clinician-scientist positions in partnership with The Christie, bridging the gap between research and bedside care. For patients like Sharon Quennell, a cancer survivor who received treatment at The Christie, the expansion represents a significant step forward for the region. Quennell, who celebrated 25 years cancer-free in 2024, highlighted that having this level of research occurring on a local level provides both hope and practical benefits for the community. The institute’s goal is to ensure that every stage of the patient journey is supported by the latest scientific evidence.
Frequently Asked Questions
- What is a biomarker in cancer research?
A biomarker is a molecule or gene found in blood, tissue, or other body fluids that serves as a sign of an abnormal process or a specific cancer type, helping doctors choose the most effective therapy. - Where is the new research facility located?
The research is based in the University of Manchester’s Paterson building, which is physically connected to The Christie hospital. - How many new staff will the center recruit?
The expansion is expected to attract 100 world-leading researchers and support staff to Manchester once the facility is fully established.
Stay Updated on Medical Breakthroughs
Want to stay informed about the latest advancements in cancer research and clinical trials? Subscribe to our newsletter for weekly updates on how science is changing patient care.


